The breakthrough could significantly improve outcomes for pancreatic cancer patients, a group that has historically faced low survival rates. However, the drug's long-term efficacy and potential side effects remain under study. If successful, daraxonrasib could also transform treatment protocols for other types of cancer, potentially benefiting millions worldwide.